Actuate Therapeutics Inc (ACTU)
NASDAQ: ACTU
· Real-Time Price · USD
11.64
1.07 (10.12%)
At close: May 30, 2025, 3:59 PM
12.00
3.09%
After-hours: May 30, 2025, 05:00 PM EDT
10.12% (1D)
| Bid | 11.1 |
| Market Cap | 228.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.31M |
| EPS (ttm) | -3.15 |
| PE Ratio (ttm) | -3.7 |
| Forward PE | -8.02 |
| Analyst | Buy |
| Ask | 12 |
| Volume | 274,361 |
| Avg. Volume (20D) | 50,724 |
| Open | 10.69 |
| Previous Close | 10.57 |
| Day's Range | 10.71 - 11.99 |
| 52-Week Range | 5.51 - 11.96 |
| Beta | 0.67 |
About ACTU
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACTU
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACTU stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-6.88%
ACTU stock has given up its prior gain. Actuate Th...
Unlock content with
Pro Subscription
3 weeks ago
-6.88%
Actuate Therapeutics shares are trading higher after the company announced elraglusib combined with GnP met its primary endpoint in its ongoing Phase 2 trial.